Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
An update from Fate Therapeutics ( (FATE) ) is now available.
Fate Therapeutics announces a leadership change as Scott Wolchko steps down as CEO, with Bob Valamehr taking over on January 1, 2025. Under Wolchko’s decade-long leadership, the company advanced in iPSC-derived cellular immunotherapies, treating over 300 patients. Valamehr, who led the company’s research and development, aims to continue innovating in cellular therapeutics, including ongoing clinical trials of the FT819 product. This transition marks a pivotal moment for Fate Therapeutics, maintaining its mission to develop groundbreaking off-the-shelf therapies for cancer and autoimmune disorders.
For a thorough assessment of FATE stock, go to TipRanks’ Stock Analysis page.
Trending Articles
- ZMI, TBAL: 2 Canadian Balanced ETFs to Shield Your Returns
- Class Action Lawsuit Against Paragon 28, Inc. (NYSE:FNA)
- 3 Penny Stocks to Watch Now, 11/29/24
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
